早期乳腺癌前哨淋巴结活检:ASCO指南更新
ASCO专家组基于2016年1月至2024年5月的系统文献综述更新早期乳腺癌初始手术中前哨淋巴结活检(SLNB)的推荐。共纳入11项随机临床试验、8项荟萃分析和/或系统综述及1项前瞻性队列研究,采用非正式共识形成推荐。推荐涉及特定低危患者可不行常规SLNB、部分患者可豁免腋窝淋巴结清扫(ALND)等。
要点
- 绝经后≥50岁、术前腋窝超声阴性、1-2级、≤2 cm、激素受体阳性、HER2阴性且接受保乳治疗的患者,临床医生不应推荐常规SLNB。
- 临床淋巴结阴性、≤5 cm浸润性乳腺癌接受乳房切除且1-2枚前哨淋巴结阳性者,可考虑术后放疗(含区域淋巴结照射)并省略ALND。
- 早期乳腺癌无淋巴结转移者不应推荐ALND;1-2枚前哨淋巴结转移且接受保乳手术加全乳放疗(±区域淋巴结照射)者不应推荐ALND。
核心结论
- ASCO专家组基于系统文献综述更新了早期乳腺癌初始手术中SLNB及ALND的实践推荐,涵盖特定低危患者省略SLNB、部分患者省略ALND等情形。
研究设计与样本
- ASCO召集专家组,基于2016年1月至2024年5月的系统文献综述制定更新推荐,纳入11项随机临床试验(14篇出版物)、8项荟萃分析和/或系统综述及1项前瞻性队列研究,采用非正式共识形成推荐。
主要发现
- 系统综述共纳入11项随机临床试验(14篇出版物)、8项荟萃分析和/或系统综述及1项前瞻性队列研究符合纳入标准。
关键数值与推荐
- 临床医生不应推荐对绝经后且≥50岁、术前腋窝超声阴性、1-2级、小(≤2 cm)、激素受体阳性、人表皮生长因子受体2阴性且接受保乳治疗的特定患者行常规SLNB。
- 临床医生可对临床淋巴结阴性、≤5 cm浸润性乳腺癌接受乳房切除且1-2枚前哨淋巴结阳性的患者提供术后放疗(含区域淋巴结照射)并省略ALND。
- 临床医生可对cT3-T4c或多中心肿瘤(临床淋巴结阴性)或接受乳房切除的导管原位癌患者,以及肥胖、男性、妊娠或既往有乳房或腋窝手术史的患者提供SLNB。
- 临床医生不应推荐对无淋巴结转移的早期乳腺癌患者行ALND,也不应推荐对1-2枚前哨淋巴结转移且将接受保乳手术加全乳放疗(±区域淋巴结照射)的早期乳腺癌患者行ALND。
临床怎么用
- 本指南经美国放射肿瘤学会(ASTRO)认可,临床医生可依据上述推荐在特定早期乳腺癌患者中省略SLNB或ALND,并在部分患者中提供SLNB。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To update the ASCO evidence-based recommendations on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer treated with initial surgery. METHODS: ASCO convened an Expert Panel to develop updated recommendations based on a systematic literature review (January 2016-May 2024). RESULTS: Eleven randomized clinical trials (14 publications), eight meta-analyses and/or systematic reviews, and one prospective cohort study met the inclusion criteria for this systematic review. Expert Panel members used available evidence and informal consensus to develop practice recommendations. RECOMMENDATIONS: Clinicians should not recommend routine SLNB in select patients who are postmenopausal and ≥50 years of age and with negative findings on preoperative axillary ultrasound for grade 1-2, small (≤2 cm), hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer and who undergo breast-conserving therapy. Clinicians may offer postmastectomy radiation (RT) with regional nodal irradiation (RNI) and omit axillary lymph node dissection (ALND) in patients with clinically node-negative invasive breast cancer ≤5 cm who receive mastectomy and have one to two positive sentinel nodes. Clinicians may offer SLNB in patients who have cT3-T4c or multicentric tumors (clinically node-negative) or ductal carcinoma in situ treated with mastectomy, and in patients who are obese, male, or pregnant, or who have had prior breast or axillary surgery. Clinicians should not recommend ALND for patients with early-stage breast cancer who do not have nodal metastases, and clinicians should not recommend ALND for patients with early-stage breast cancer who have one or two sentinel lymph node metastases and will receive breast-conserving surgery and whole-breast RT with or without RNI.Additional information is available at www.asco.org/breast-cancer-guidelines.This guideline has been endorsed by the American Society for Radiation Oncology (ASTRO).
引用
- Park KU, Somerfield MR, Anne N, et al. Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2025. PMID: 40209128. doi:10.1200/JCO-25-00099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。